JG
MACK

Joel Greenblatt’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Joel Greenblatt’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,707
Closed -$160K – 1108
2015
Q1 		$160K Buy
+1,707
New +$145K ﹤0.01% 870

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
LIM
Lagoda Investment Management New York $182M AUM 58.16% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Joel Greenblatt's MACK Position: Q2 2015 in Review

Joel Greenblatt sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2015, closing a stake of 1,707 shares — an estimated $160K sold.

Joel Greenblatt first reported a position in MACK in Q1 2015 and held it in 1 quarter. The position peaked at $160K in Q1 2015. 150 funds tracked by Wall St. Rank hold MACK as of Q2 2015.

  • Joel Greenblatt reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Joel Greenblatt sold 1,707 Merrimack Pharmaceuticals, Inc. shares in Q2 2015, an estimated $160K.
  • Joel Greenblatt first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Joel Greenblatt's Merrimack Pharmaceuticals, Inc. position peaked at $160K in Q1 2015.
  • 150 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2015.

Based on Gotham Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.